期刊信息查詢系統

期刊標題檢索 ENDOCR METAB IM 最新評論: One meta-analysis, submitted on April 13th, revised on August 23rd, ... (2024-09-10)

[Endocrine Metabolic & Immune Disorders-Drug Targets]您好，您是該頁面的第 21242 位訪客。

期刊簡介

期刊名稱

Endocrine Metabolic & Immune Disorders-Drug Targets
LetPub Score

5.3

50 ratings

Rate

Reputation

6.3

Influence

3.8

Speed

8.5

期刊簡稱

ENDOCR METAB IMMUNE

ISSN

1871-5303

E-ISSN

2212-3873

h-index

CiteScore

SJR

SNIP

CiteScore Rank

4.60

0.495

0.541

Subject field	Quartiles	Rank	Percentile
Category: Medicine Subcategory: Endocrinology, Diabetes and Metabolism	Q2	119 / 244
Category: Medicine Subcategory: Immunology and Allergy	Q3	131 / 233

自引率 (2023-2024)

5.00%自引率趨勢

掲載範囲

Aims & Scope

This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.

官方網站

http://benthamscience.com/journal/index.php?journalID=emiddt

在線稿件提交

http://bsp-cms.eurekaselect.com/index.php/CDTIEMD

開放訪問

出版商

Bentham Science Publishers B.V.

主題領域

ENDOCRINOLOGY & METABOLISMIMMUNOLOGY

出版國/地區

U ARAB EMIRATES

發行頻率

創刊年

每年文章數

176每年文章數趨勢

黃金OA百分比

1.65%

Web of Science 四分位
（ 2023-2024）

WOS Quartile: Q3

Category	Edition	JIF Quartile	JIF Ranking	JIF Percentage
ENDOCRINOLOGY & METABOLISM	SCIE	Q3	134/186
IMMUNOLOGY	SCIE	Q4	144/181
PHARMACOLOGY & PHARMACY	SCIE	Q3	222/354

索引 (SCI or SCIE)

Science Citation Index Expanded

鏈接到PubMed Central (PMC)

https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1871-5303%5BISSN%5D

平均審稿時間 *

來自出版商的數據:
來自作者的數據:

競爭力 *

來自作者的數據:

參考鏈接

相關期刊	【Endocrine Metabolic & Immune Disorders-Drug Targets】CiteScore趨勢
自引率趨勢	每年文章數趨勢
作者評論

*所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。

同一學科的期刊
CiteScore趨勢
自引率趨勢
每年文章數趨勢

學科內的可信期刊	影響因子
Science Immunology	H-index: 0 CiteScore: 32.90
Journal of Allergy and Clinical Immunology-In Practice	H-index: 40 CiteScore: 11.10
Cancer Immunology Research	H-index: 62 CiteScore: 15.60
npj Vaccines	H-index: 8 CiteScore: 11.90
OncoImmunology	H-index: 58 CiteScore: 12.80
OncoImmunology	H-index: 49 CiteScore: 12.80
HLA	H-index: 93 CiteScore: 3.00
ALLERGOLOGY INTERNATIONAL	H-index: 45 CiteScore: 12.60
Immunity & Ageing	H-index: 38 CiteScore: 10.20
Clinical and Translational Allergy	H-index: 28 CiteScore: 7.50

學科內最受檢索的期刊	頁面查看次數
Journal of Inflammation Research	74904
OncoImmunology	59297
Cancer Immunology Research	58458
OncoImmunology	50779
Science Immunology	40604
npj Vaccines	29950
Human Vaccines & Immunotherapeutics	25054
Human Vaccines & Immunotherapeutics	24972
Journal of Allergy and Clinical Immunology-In Practice	19219
Allergy Asthma & Immunology Research	19010

明年預測:
穩步上升無變化逐步下降　刷新

首頁上一頁 1 下一頁末頁 (頁 /1)
[Endocrine Metabolic & Immune Disorders-Drug Targets] 的評論	撰寫評論

作者: keyanlabourer 領域: 医学審稿時間: 0.0 month(s) 結果: 待定＆不明撰寫評論	2024-09-10 13:32:38 評論於 One meta-analysis, submitted on April 13th, revised on August 23rd, accepted on September 27th, with excellent editing and ongoing positive communication with the editor. (0) 讚！ \| keyanlabourer
作者: YSL 領域: 医学審稿時間: 5.0 month(s) 結果: 修改後接受撰寫評論	2018-08-28 17:42:03 評論於 The number of papers published each year is low, so it is not easy to get accepted here. The reviewers asked some questions that are not easy to answer. (0) 讚！ \| YSL

首頁上一頁 1 下一頁末頁 (頁 /1)

開始撰寫 [Endocrine Metabolic & Immune Disorders-Drug Targets] 的評論：

您的評論將是選擇期刊的重要參考信息。歡迎分享您的投稿經驗！
研究領域:
接受狀態:	審稿時間: 個月以內
您的評論:
姓名:	(建議: 請輸入有效的電子郵件地址以便與審稿者互動，或註冊LetPub帳戶。)
給管理員留言:	我的評論包含修正信息如果您發現該期刊頁面中有錯誤的信息或希望提供額外內容，請勾選此框。管理員將檢查並儘快更新期刊說明。
隨機碼:	點擊刷新

期刊名稱:	ISSN:	主題領域:	影響因子範圍: -
索引:	類別:	開放訪問:	排序方式:

作者: keyanlabourer 領域: 医学審稿時間: 0.0 month(s) 結果: 待定＆不明撰寫評論	2024-09-10 13:32:38 評論於 One meta-analysis, submitted on April 13th, revised on August 23rd, accepted on September 27th, with excellent editing and ongoing positive communication with the editor. (0) 讚！ \| keyanlabourer
作者: YSL 領域: 医学審稿時間: 5.0 month(s) 結果: 修改後接受撰寫評論	2018-08-28 17:42:03 評論於 The number of papers published each year is low, so it is not easy to get accepted here. The reviewers asked some questions that are not easy to answer. (0) 讚！ \| YSL

首頁上一頁 1 下一頁末頁 (頁 /1)

Endocrine Metabolic & Immune Disorders-Drug Targets

期刊標題檢索 ENDOCR METAB IM 最新評論: One meta-analysis, submitted on April 13th, revised on August 23rd, ... (2024-09-10)

[Endocrine Metabolic & Immune Disorders-Drug Targets]您好，您是該頁面的第 21242 位訪客。

開始撰寫 [Endocrine Metabolic & Immune Disorders-Drug Targets] 的評論：

Contact us